Loading...
•
Mar 31, 2024
Y-mAbs Q1 2024 Earnings Report
Y-mAbs' first quarter results for 2024 were reported, featuring U.S. DANYELZA® net product revenues of $18.6 million, and worldwide DANYELZA net product revenues of $19.4 million.
Key Takeaways
Y-mAbs reported its Q1 2024 financial results, highlighting the highest quarter of U.S. demand for DANYELZA® since its launch and progress in clinical development initiatives, particularly the SADA PRIT Technology platform. The company's financial guidance for the full year 2024 was reiterated, expecting to continue operations into 2027.
U.S. DANYELZA® net product revenues reached $18.6 million, an 11% increase year-over-year.
Worldwide DANYELZA net product revenues were $19.4 million, a 4% decrease year-over-year.
Cash and cash equivalents totaled $75.7 million as of March 31, 2024, with a cash burn of $2.9 million for the quarter.
Full year 2024 financial guidance and anticipated cash runway into 2027 were reiterated.
Y-mAbs
Y-mAbs
Y-mAbs Revenue by Segment
Y-mAbs Revenue by Geographic Location
Revenue by Segment
DANYELZA Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comEx-U.S. Revenue
CapyFin.com Forward Guidance
Management reiterated its full year 2024 financial guidance.
Positive Outlook
- Anticipated total DANYELZA® net product revenues of between $95 million and $100 million.
- Anticipated operating expenses of between $115 million and $120 million.
- Anticipated total annual cash burn of between $15 million and $20 million.
- Cash and cash equivalents anticipated to continue to support operations as currently planned into 2027.